sacubitril/valsartan

Sacubitril/Valsartan (LCZ696) is an orally bioavailable, dual angiotensin II receptor and neprilysin inhibitor for the treatment of hypertension and heart failure.

Sacubitril hemicalcium salt (AHU377 calcium salt) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696. Sacubitril hemicalcium salt is a prodrug of LBQ657, which is an inhibitor of the zinc metallopeptidase neprilysin. Neprilysin degrades a variety of vasoactive peptides such as atrial and brain natriuretic peptide, bradykinin, adrenomedullin, and endothelin-1. Inhibition of neprilysin leads to an increased level of these peptides and, thus, antihypertensive effects. Formulations containing AHU377 in combination with the angiotensin II receptor antagonist valsartan are used to treat hypertension and heart failure.

2R,4R-Sacubitril is an impurity of Sacubitril, which is used in combination with valsartan for the treatment of patients with heart failure.

2S,4R-Sacubitril is an impurity of Sacubitril, which is used in combination with valsartan [for the treatment of patients with heart failure].

(Z)2S,4R-Sacubitril is an impurity of Sacubitril, a compound used in combination with valsartan for treating patients with heart failure.